Cancer Research UK CTU gets £4.5mn for pancreatic cancer research
Date: 2018-02-15   Author: Dhananjay Punekar  Category: #news

Cancer Research UK CTU gets £4.5mn for pancreatic cancer research

The Cancer Research UK, a charitable organization in the UK focusing on cancer research & healthcare, has offered funds worth £4.5 million for the Cancer Research UK Clinical Trials Unit (CTU) in Scotland after assessing a review report of all its clinical trial units. Sources state that the Cancer Research UK CTU in Scotland was one of the eight sites to receive funds from the Cancer Research UK.

For the record, the UK based charitable institution has already allotted funds worth £10 million for Cancer Research UK Clinical Trials Unit to conduct a study that will help in differentiating between pancreatic cancer patients based on the molecular makeup of their cancer lumps during the three clinical tests. One of the researchers working at the firm has stated that subjects diagnosed with pancreatic cancer send their tumor cells to the CTU lab for genetic testing. He further claimed that based on the test results, the patient is advised to undergo clinical tests that suits a particular disease type, thereby helping the physicians to offer better treatment to the patient and prevent side effects.

According to BBC News, scientists at the Glasgow University based center have been carrying out extensive research since long to unearth new ways of treating patients with lung cancer, pancreatic cancer, brain tumors, and prostate cancers to improve the rate of patient survival.

Reportedly, around 32,000 persons in Scotland are diagnosed with some form of cancer on an annual basis, with rising cancer cases witnessed among women. The overall survival rate in cancer patients has increased in the country over the last four decades and today, nearly half of the patients survive the disease for nearly 10 years. Experts claim that the research carried out in the institutions such as Cancer Research UK will thus contribute toward increasing patient survival rate to at least 75% by 2034.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Atomwise to collaborate with Hansoh Pharma for AI-based drug discovery
Author: Pankaj Singh

Atomwise Inc., a leading developer of healthcare software that uses AI to discover medicines and agricultural compounds, recently announced that it will be collaborating with Hansoh Pharmaceutical Group Company Limited, a leading Chinese biopharma...


Valsoft acquires Commsoft OASES and enters the aviation vertical
Author: Pankaj Singh

  • Since the company’s first association with airline sector over 40 years ago, Communications Software has been developing the MRO IT system continually.
  • London-based Snyk secures €63Mn from Accel led funding round
    Author: Saipriya Iyer

    The company intends to use this funding to fuel its plans for the next phase of global growth.

    Snyk, a developer-first security company based in London, has repor...